These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12171723)

  • 1. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation.
    Novitzky N; Rouskova A
    Cytotherapy; 2001; 3(3):165-73. PubMed ID: 12171723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAMPATH-1M T-cell depleted BMT for SCID: long-term follow-up of 19 children treated 1987-98 in a single center.
    Gennery AR; Dickinson AM; Brigham K; Barge D; Spickett GP; Curtis A; Spencer V; Jackson A; Cavanagh G; Carter V; Palmer P; Flood TJ; Cant AJ; Abinun M
    Cytotherapy; 2001; 3(3):221-32. PubMed ID: 12171729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 9. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
    Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
    Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
    Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
    Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Friends, faithfulness and fortunes.
    Hale G
    Cytotherapy; 2001; 3(3):135-6. PubMed ID: 12171720
    [No Abstract]   [Full Text] [Related]  

  • 18. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients.
    Seth T; Kanga U; Sood P; Sharma V; Mishra P; Mahapatra M
    Transplant Proc; 2012 May; 44(4):922-4. PubMed ID: 22564586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
    Willemze R; Richel DJ; Falkenburg JH; Hale G; Waldmann H; Zwaan FE; Fibbe WE
    Bone Marrow Transplant; 1992 Apr; 9(4):255-61. PubMed ID: 1600413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
    Norlin AC; Remberger M
    Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.